Impact of brain biopsy on management of nonneoplastic brain disease

Introduction: Diagnostic yield of brain biopsy in neoplastic brain disease is high and its clinical impact is well established. In nonneoplastic brain disease with negative conventional investigation, decision to undergo invasive procedures is difficult due to its inherent risk and known lower diagnostic yield. Research question: What is the clinical impact of brain biopsy results on management of nonneoplastic brain disease ? Material and methods: A multidisciplinary team retrospectively reviewed and included all nonneoplastic brain disease cases submitted to biopsy between 2009 and 2019, in a tertiary hospital in Lisbon. Baseline characteristics were registered, including immunosuppression status, diagnostic workup, and treatment prior to biopsy. Diagnostic yield, clinical impact and in-hospital complication rates were assessed. Results: Sixty-four patients were included, 20 (31.3%) of them immunosuppressed (15 HIV ​+ ​patients). Thirty-five (67.7%) were previously treated with steroids or antiinfectious agents, with higher percentage (93.3%) in the immunosuppressed group. Biopsy results were diagnostic in 46 (71.9%) cases. More frequent diagnosis was infectious in 20 (31.2%), neoplastic in 12 (18.8%) and inflammatory diseases in 8 (12.5%). Brain biopsy resulted on impact on patient's clinical management in 56 (87.5%), of which 37(57.8%) were submitted to treatment change. In-hospital complications were registered in 4 (6.6%) patients. Discussion and conclusion: Brain biopsy had clinical impact, including a change in treatment, in most patients studied, and may be considered a useful diagnostic option in nonneoplastic brain disease. However, associated complication rate is not negligible, and previous thorough workup, patient selection and risk-benefit assessment are important.info:eu-repo/semantics/publishedVersio

Deep brain stimulation of the anterior nucleus of the thalamus in drug-resistant epilepsy in the MORE multicenter patient registry

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Background and objectives: The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) in patients with drug-resistant epilepsy (DRE) was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT DBS therapy in routine clinical practice. Methods: MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 centers from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), responder rate (RR), health-related quality of life (Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes. Results: Of the 191 patients recruited, 170 (mean [SD] age of 35.6 [10.7] years, 43% female) were implanted with DBS therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment. The median monthly SF decreased by 33.1% from 15.8 at baseline to 8.8 at 2 years (p 10 implantations) had 42.8% reduction in median monthly SF by 2 years in comparison with 25.8% in low-volume center. In patients with cognitive impairment, the reduction in median monthly SF was 26.0% by 2 years compared with 36.1% in patients without cognitive impairment. The most frequently reported adverse events were changes (e.g., increased frequency/severity) in seizure (16%), memory impairment (patient-reported complaint, 15%), depressive mood (patient-reported complaint, 13%), and epilepsy (12%). One definite sudden unexpected death in epilepsy case was reported. Discussion: The MORE registry supports the effectiveness and safety of ANT DBS therapy in a real-world setting in the 2 years following implantation. Classification of evidence: This study provides Class IV evidence that ANT DBS reduces the frequency of seizures in patients with drug-resistant focal epilepsy.The MORE registry was sponsored and funded by Medtronic, plc.info:eu-repo/semantics/publishedVersio

O cuidado pré-natal em hospital universitário: uma avaliação de processo Prenatal care in an university hospital: evaluating the process

O objetivo do estudo foi avaliar o processo de atenção pré-natal referente à utilização do cuidado pré-natal do Programa Assistência Pré-natal às Gestantes de Baixo Risco do Hospital Universitário de Maringá, Paraná, Brasil. Compreendeu a seleção de critérios de qualidade que avaliaram a precocidade no ingresso e a adequação do número de consultas de pré-natal, mensuradas conforme o Programa de Humanização do Pré-natal e Nascimento do Ministério da Saúde e Índice de Adequação da Utilização do Cuidado Pré-natal. O estudo demonstrou que 44,5% gestantes iniciaram tardiamente o pré-natal, o que pode sugerir uma oferta limitada de vagas e a busca por melhor qualidade na atenção, demonstrada pela transferência espontânea de gestantes de outros serviços para o programa. As consultas de pré-natal foram garantidas, sendo o número médio &shy; 9,8 consultas por gestante &shy; superior aos parâmetros nacionais recomendados. Os indicadores utilizados e desenvolvidos para a avaliação de processo identificaram que o serviço ainda apresenta obstáculos ao acesso organizacional, necessitando, assim, da definição de estratégias que garantam essa diretriz fundamental do SUS.<br>The objective of this study was to evaluate the prenatal care process referring to the Prenatal Assistance to Low Risk Pregnant Women Program of the University Hospital of Maringá, Paraná State, Brazil. It was made a selection of quality criteria which evaluate the precocity in the process and the adequacy in the number of consultation during prenatal period, measured by the Humanization Program of Prenatal and Birth of the Health Ministry and the adequacy on the use of the prenatal care. The study showed that 44.5% of pregnant women started late the prenatal care suggest of the low offer and search to better quality care, which is manifested by spontaneous transference of pregnant women to other services to the program. The prenatal consultations were confirmed and the results showed a mean of 9.8 consultations per pregnant woman &shy; higher than the recommended national parameters. The indicators used and developed to the evaluation of process still present some obstacles to the organizational access and need to define strategies which guarantee this fundamental policy of the Brazilian Unified Health System